Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | RO7310729 |
| Synonyms | |
| Therapy Description |
RO7310729 (XmAb24306) is a IL15 - IL15Ralpha complex fused to a bispecific Fc domain, that stimulates proliferation of NK cells and T-cells (NCI Thesaurus). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| RO7310729 | XmAb24306|RO-7310729|RO 7310729 | RO7310729 (XmAb24306) is a IL15 - IL15Ralpha complex fused to a bispecific Fc domain, that stimulates proliferation of NK cells and T-cells (NCI Thesaurus). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT04250155 | Phase I | RO7310729 Atezolizumab + RO7310729 | An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | Active, not recruiting | USA | NLD | ITA | ESP | CAN | BRA | BEL | AUS | 1 |